Atomoxetine Hydrochloride(at oh mox’ ah teen)
Strattera
PREGNANCY CATEGORY C
Drug class
Selective norepinephrine reuptake inhibitor
Therapeutic Actions
Selectively blocks the reuptake of norepinephrine at the neuronal synapse. The mechanism by which this action has a therapeutic effect in ADHD is not understood.
Indications
Treatment of ADHD as part of a total treatment program
Unlabeled uses: Treatment of obesity, binge eating disorder, nocturnal enuresis
Contraindications and Cautions
Contraindicated with hypersensitivity to atomoxetine or constituents of Strattera; use of MAOIs within the past 14 days; narrow-angle glaucoma; pheochromocytoma.
Use cautiously with hypertension, tachycardia, CV or cerebrovascular disease, pregnancy, lactation, severe hepatic impairment.
Available Forms
Capsules—10, 18, 25, 40, 60, 80, 100 mg
Dosages
Adults and children weighing more than 70 kg
40 mg/day PO, increase after a minimum of 3 days to a target total daily dose of 80 mg PO given as a single dose in the morning or two evenly divided doses, in the morning and late afternoon or early evening; after 2–4 additional wk, total dosage may be increase to a maximum of 100 mg/day if needed.
Pediatric patients 6 yr and older weighing 70 kg or less
Initially, 0.5 mg/kg/day PO; increase after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg/day PO as a single daily dose in the morning; may be given in two evenly divided doses in the morning and late afternoon or early evening. Do not exceed 1.4 mg/kg or 100 mg/day, whichever is less.
Patients with hepatic impairment
For moderate hepatic impairment (Child-Pugh class B), reduce dose to 50% of the normal dose; for severe hepatic impairment (Child-Pugh class C), reduce dose to 25% of the normal dose.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
